Phs 398 (rev. 9/04), biographical sketch format page
CURRENT POSITIONS Chief, Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan Director, Institute of Clinical Medical Science, China Medical University Medical College, Taichung, Taiwan Professor, Institute of Clinical Medical Science, China Medical University Medical College, Taichung, Taiwan Adjunct Professor, Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University RESEARCH INTEREST Neuropsychopharmacology Phramcogenomics Psychiatric genetics Cognitive neuroscience HONORS 1996,1997,1998 Young Investigator Award, National Science Council, Taiwan 1999, 2000 Senior Investigator Award, National Science Council, Taiwan 2005
A-class Research Award, National Science Council, Taiwan (for 3 years)
2005 Distinguished Investigators Award, China Medical University, Taiwan 2006
Y.Z. Hsu Scientific Paper Award, Biotechnology Category, Taiwan
Schizophrenia Research Award, Society of Psychiatry, Taiwan (since 2008, this award is limited to a maximum of 3 times)
2007 Distinguished Research Paper Award, National Cheng Kung University Medical College, Taiwan 2007
Distinguished Investigators Award, China Medical University, Taiwan (for 3 years)
2008 Distinguished Research Paper Award, China Medical University, Taiwan EDITORIAL BOARD 2004-2007, Psychiatry and Clinical Neuroscience 2007-present, The Open Nitric Oxide Journal REVIEWER 2004, Journal of Clinical Psychopharmacology (3 papers) 2005, Prog Neuropsychopharmacol & Biol Psychiatry (2 papers) 2005, Acta Pharmacologica Sinica 2005, The Journal of Nutritional Biochemistry 2005, Biological Psychiatry (2 papers) 2006, World Journal of Biological Psychiatry 2006, Journal of Formosan Medical Association (2 papers) 2006, Chinese Journal of Physiology 2006, Psychiatry Research 2006, Journal of Clinical Psychopharmacology (3 papers) 2006, Future Neurology 2006, Journal of Affective Disorder
中國醫藥大學 臨床醫學研究所
Graduate Institue of Clinical Medical Science, China Medical University
2007, Journal of Formosan Medical Association (2 papers) 2007, BMC Psychiatry 2007, Comprehensive Psychiatry 2007, Human Psychopharmacology: Clinical and Experimental 2007, Journal of Biomedical Science 2007, World Journal of Biological Psychiatry 2007, The Journal of Nutritional Biochemistry 2007, The Pharmacogenomics Journal 2007, Pharmacogenomics 2007, Journal of Psychopharmacology 2007, Biological Psychiatry (3 papers) 2008, Journal of Psychiatry Research (2 papers) 2008, Psychiatry Research 2008, The Chinese Journal of Physiology 2008, Lipids in Health and Disease 2008, Journal of Formosan Medical Association (2 papers) 2008, World Journal of Biological Psychiatry (2 papers) 2008, Personalized Medicine 2008, Expert Review of Neurotherapeutics 2008, Pharmacogenomics 2008, Journal of Clinical Psychopharmacology (2 papers) 2008, Journal of Psychopharmacology 2008, Schizophrenia Research 2009, BMJ Case Reports 2009, Journal of Formosan Medical Association 2009, Journal of Clinical Psychopharmacology 2009, Biological Psychiatry
PEER-REVIEWED PUBLICATIONS (SINCE 2004) 1. Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH (2004): Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophrenia Research 67:63-70 (sci)
Tsai G, Lane HY*, Yang P, Chong MY, Lange N (2004): Glycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 55:452-456 (sci) [*shared first author] Lane HY, Chang YC, Chiu CC, Lee SH, Lin CY, Chang WH (2004): Fine-tuning risperidone dosage for acute schizophrenia: clinical determinants Psychopharmacology 172:393-399 (sci)
Su KP, Lane HY, Chuang CL, Chen KP, Shen WW (2004): Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome. Schizophrenia Research 66:191-192 (sci) Lane HY, Huang CL, Lin CY, Chang WH (2004): NMDA modulation and schizophrenia. Current Topics in Pharmacology 8:305-312
Lu ML, Lane HY*, Lin SK, Chen KP, Chang WH (2004): Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Journal of Clinical Psychiatry 65: 766-771 (sci) [*corresponding author] Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH (2004): Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. International Journal of Neuropsychopharmacology 7:461-470 (sci)
Liu YC, Huang CH, Lane HY* (2004): N-methyl-D-aspartate (NMDA) Hypothesis of Schizophrenia. Taiwanese Journal of Psychiatry 18: 172-180 [*corresponding author]
Chiu CC, Lane HY, Huang MC, Liu HC, Jann MW, HonYY, Chang WH, Lu ML (2004): Dose-dependent alternations in oral bioavailability and clearance of olanzapine during coadministration of fluvoxamine in schizophrenic patients. Journal of Clinical Pharmacology 44: 1385-1390 (sci)
10. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH (2005): Dopamine D3 receptor Ser9Gly
polymorphism and risperidone response: a rigorous pharmacogenetic study. Journal of Clinical Psychopharmacology 25:6-11 (sci)
11. Sun HS, Fann CSJ, Lane HY, Chang YT, Chang CJ, Liu YL, Cheng ATA (2005). A functional polymorphism in
the promoter region of the tryptophan hydroxylase (TPH1) gene is associated with alcohol dependence in one aboriginal group in Taiwan. Alcoholism: Clinical and Experimental Research 29:1-7 (sci)
中國醫藥大學 臨床醫學研究所
Graduate Institue of Clinical Medical Science, China Medical University
12. Lane HY, Lee CC, Liu YC, Chang WH (2005): Pharmacogenetic studies of response to risperidone and other
newer atypical antipsychotics. Pharmacogenomics 6:139-149 (sci)
13. Chiu CC, Lane HY*, Huang MC, Liu HC, Jann MW, HonYY, Chang WH, Lu ML (2005): Regular-dose
risperidone on QTc intervals. Journal of Clinical Psychopharmacology 25:391-393 (sci) [*corresponding author]
14. Chen CM, Lane HY*, Wu YR, Ro LS, Chen FL, Hung WL, Hou YT, Lin CY, Huang SY, Chen I C, Soong BW,
Li ML, Hsieh-Li HM, Su MT, Lee-Chen GJ (2005): Expanded trinucleotide repeats in the TBP/SCA17 gene, but not the KLHL1AS/SCA8 and PPP2R2B/SCA12 genes, are associated with schizophrenia. Schizophrenia Research 78:131-136 (sci) [*corresponding author]
15. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai G (2005): Sarcosine (N-methylglycine) or D-serine add-on
treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry 62:1196-1204 (sci)
16. Hsieh CL, Chang QY, Lin IH, Lin JG, Liu CH, Tang NY, Lane HY* (2006): The study of electroacupuncture on
cerebral blood flow in rats with and without cerebral ischemia. American Journal of Chinese Medicine 34:351-361 (sci) [*corresponding author]
17. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH (2006): Risperidone-related weight gain:
genetic and nongenetic predictors. Journal of Clinical Psychopharmacology 26:128-134 (sci)
18. Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G (2006): Glycine transporter I
inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological Psychiatry 60:645-649 (sci)
19. Loh EW, Lane HY, Chen CH, Chang PS, Ku LW, Wang KHZ, Cheng ATA (2006): Glutamate decarboxylase
genes and alcoholism in Han Taiwanese men. Alcoholism: Clinical and Experimental Research 30:1817-1823 (sci)
20. Chang YC, Lane HY, Yang KH, Huang CL (2006): Optimizing early prediction for antipsychotic response in
schizophrenia. Journal of Clinical Psychopharmacology 26:554-559 (sci)
21. Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, Lane HY* (2007): Early prediction of clinical response in
schizophrenia patients receiving atypical antipsychotic zotepine. The Journal of Clinical Psychiatry 68:1522-1527 (sci) [*corresponding author]
22. Lane HY, Liu YC, Huang CL, Hsieh CL, Chang YL, Chang L, Chang YC, Chang WH (2008): Prefrontal
executive function and D1, D3, 5-HT2A, and 5-HT6 receptors gene variations in healthy participants. Journal of Psychiatry and Neuroscience 33:47-53 (sci)
23. Lin CH, Lin KS, Lin CY, Chen MC, Lane HY* (2008): Time to rehospitalization in major depression patients
taking venlafaxine or fluoxetine. The Journal of Clinical Psychiatry 69:54-59 (sci) [*corresponding author]
24. Lin YC, Chen HZ, Chang TJ, Lane HY* (2008): Hypokalemia following rapid titration of quetiapine treatment.
The Journal of Clinical Psychiatry 69:165-166 (sci) [*corresponding author]
25. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Huang CH, Tsai G (2008): RGS4 polymorphisms predict
clinical manifestations and responses to risperidone treatment in patients with schizophrenia. Journal of Clinical Psychopharmacology 28:64-68 (sci)
26. Tsai GE, Lane HY*, VanDenBerg CM, Liu YC, Tsai P, Jann MW (2008): Disposition of D-serine in Healthy
Adults. The Journal of Clinical Pharmacology 48:524-527 (sci) [*shared first author]
27. Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Tsai G (2008): Sarcosine (N-methylglycine) treatment for
acute schizophrenia: a randomized, double-blind study. Biological Psychiatry 63:9-12 (sci) (selected for the commentary article)
28. Ma WF, Lane HY, Laffrey SC (2008): A model testing factors that influence physical activity for Taiwanese
adults with anxiety. Research in Nursing and Health Apr 7 [Epub ahead of print (sci)
29. Chen CM, Hou YT, Liu JY, Wu YR, Lin CH, Fung HC, Hsu WC, Hsu Y, Lee SH, Hsieh-Li HM, Su MT, Chen ST,
Lane HY, Lee-Chen GJ (2008): PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications. Am J Med Genet B Neuropsychiatr Genet. 2008 May 15. [Epub ahead of print]
30. Lin CH, Huang CW, Chen CC, Hsu YF, Chang WH, Lane HY* (2008): Time to rehospitalization in patients with
bipolar I disorder on lithium or valproate with adjunctive antipsychotics. Psychopharmacology. Jun 20. [Epub ahead of print] [*corresponding author]
31. Lin YC, Su HK, Ouyang WC, Lane HY* (2008): Zotepine-Induced QTc prolongation. Journal of Clinical
Psychopharmacology (in press) [*corresponding author]
32. Chang JP, Tsai CH, Wu PL, Lane HY, Su KP (2009): Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
treatment for Isaacs syndrome with depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 26. [Epub ahead of print]
33. Liu YC, Huang CL, Wu PL, Chang YC, Huang CH, Lane HY* (2009): Lack of association between AKT1
variances vs. clinical manifestations and social function in patients with schizophrenia. Journal of Psychopharmacology [Epub ahead of print] [*corresponding author]
中國醫藥大學 臨床醫學研究所
Graduate Institue of Clinical Medical Science, China Medical University
34. Ma WF, Yen JW, Chen WC, Chang HJ, Huang XY, Lane HY* (2009): The roles of state and trait anxiety in
physical activity participation for Taiwanese adults with anxiety disorders. J Formos Med Assoc. (Accepted) [*corresponding authors]
35. Lane HY, Huang CL, Chang YC, Lau CH, Wu PL, Chou A, Tsai G (2009): Increased DAOA (G72) mRNA
expression in WBC of patients with schizophrenia: an NMDA diagnostic biomarker. Archives of General Psychiatry (revision under review). (sci)
36. Hsu HY, Lane HY* Association of emotion perception with DRD3 Ser9Gly polymorphism in schizophrenia
patients (2009): Psychiatry Research (in revision) [*corresponding author]
37. Lane HY, Lin C-H, Huang CL, Chang YC, Liau CH, Tsai GE (2009): A Randomized, double-blind,
placebo-controlled study of sarcosine (N-methylglycine) and D-serine add-on treatment for chronically stable schizophrenia. Neuropsychopharmacology (submitted)(sci)
US Provisional Patent Application 61/028138: A diagnostic blood test for psychosis. Guochuan.E.Tsai and Hsien.-Yuan Lane are inventors. RECENT RESEARCH SUPPORT 1.
Evaluating sarcosine, a glycine uptake inhibitor, for cognition enhancement in schizophrenia
NSC-95-2314-B-006-118-MY3 Lane (Role: PI) 8/01/06-7/31/09 National Science Council, Taiwan
NMDA modulation in schizophrenia: long-term efficacy of glycine transporter I inhibitor
NSC-97-2314-B-039-006-MY3 Lane (Role: PI) 8/01/08-7/31/11 National Science Council, Taiwan
D-amino acid oxidase inhibition for NMDA modulation of schizophrenia
Lane (Role: PI) 1/01/05-12/31/09 National Health Research Institutes, Taiwan
NMDA hypofunction of schizophrenia: diagnosis and treatment
中國醫藥大學 臨床醫學研究所
Graduate Institue of Clinical Medical Science, China Medical University
POR FAVOR LEA ESTOS TÉRMINOS Y CONDICIONES CON CUIDADO. Estos Términos y Condiciones (el “Acuerdo”) establecen los términos legalmente vinculantes para usar el sitio de Internet http://www.comedycentral.la (“Sitio”, “nosotros”, “nos”, y “nuestro”) en coordinación con el canal Comedy Central Latinoamérica (“Canal Comedy Central”) ambos operados por MTV Networks Lati
National Federations participating in the Olympic Games Re.: Anti-Doping rules - Olympic Games Beijing 2008 Special provisions for inhaled beta2 agonists or glucocoricosteroids Dear Mr. President, Dear Secretary General, Please find below some specific information regarding Anti-Doping rules for the Olympic Games Beijing 2008 and special provisions for inhaled beta2 ag
